Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

Martin Benedikt; Abderrahim Oulhaj; Ursula Rohrer; Martin Manninger; Norbert J. Tripolt; Peter N. Pferschy; Faisal Aziz; Markus Wallner; Ewald Kolesnik; Marianne Gwechenberger; Martin Martinek; Michael Nürnberg; Franz Xaver Roithinger; Clemens Steinwender; Johannes Widkal; Simon Leiter; Andreas Zirlik; Markus Stühlinger; Douglas S. Scherr; Harald Sourij; Dirk von Lewinski

doi:10.1056/evidoa2400147

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have beneficial pleiotropic effects, contributing to improved cardiovascular and renal outcomes for patients with and without diabetes. The impact of SGLT2is on arrhythmic burden remains largely unexplored through randomized trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Benedikt et al. (2024) studied this question.

synapsesocial.com/papers/68e59b44b6db6435875365c4 https://doi.org/10.1056/evidoa2400147

View Full Paper

Ask AI

Bookmark

Share

Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

Ask about this paper

Abstract

Discussion

Cite This Study

Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading